Zymeworks Inc
For the period ended Dec 31, 2023. Filed Mar 6, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 6, 2024
ZYME$31.46+2.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets as at December 31, 202 and
Consolidated Balance Sheets
(Expressed in thousands of U.S. dollars except share data)
| December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $157,557 | $400,912 |
| Short-term investments (note 5) | 216,770 | 91,320 |
| Accounts receivable | 19,477 | 33,400 |
| Prepaid expenses and other current assets | 19,122 | 19,074 |
| Total current assets | 412,926 | 544,706 |
| Deferred financing fees | 108 | 10 |
| Long-term investments (note 5) | 82,148 | 886 |
| Long-term prepaid assets | 7,240 | 15,729 |
| Deferred tax asset (note 14) | 3,615 | 1,345 |
| Property and equipment, net (note 7) | 19,847 | 24,713 |
| Operating lease right-of-use assets (note 15) | 17,696 | 22,937 |
| Intangible assets, net (note 8) | 7,656 | 8,755 |
| Acquired in-process research and development (note 6) | 17,628 | 17,628 |
| Goodwill (note 6) | 12,016 | 12,016 |
| Total assets | $580,880 | $648,725 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable and accrued liabilities (note 9) | $45,032 | $87,468 |
| Income tax payable (note 14) | 1,811 | 840 |
| Fair value of liability-classified stock options | 960 | 1,642 |
| Current portion of operating lease liability (note 15) | 4,261 | 3,322 |
| Deferred revenue and other consideration (note 12) | 3,699 | 2,353 |
| Total current liabilities | 55,763 | 95,625 |
| Long-term portion of operating lease liability (note 15) | 22,369 | 24,667 |
| Deferred revenue (note 12) | 32,941 | 30,588 |
| Other long-term liabilities (note 9) | 1,701 | 3,101 |
| Deferred tax liability (note 14) | 3,300 | 1,788 |
| Total liabilities | 116,074 | 155,769 |
| Stockholders’ equity: | ||
| Common shares, $0.00001 par value; 900,000,000 authorized shares of common stock at December 31, 2023 and December 31, 2022 (70,115,997 and 63,059,501 shares issued and outstanding at December 31, 2023 and 2022, respectively (note 10b). | 997,227 | 886,322 |
| Preferred shares, $0.00001 par value; 100,000,000 authorized shares of preferred stock, out of which, one share of preferred stock is a share of Special Voting Preferred Stock and outstanding as of December 31, 2023 and December 31, 2022 (note 10b). | — | — |
| Exchangeable shares, no par value, 651,219 issued and outstanding shares at December 31, 2023 (December 31, 2022: 1,424,533) (note 10b). | 9,345 | 20,442 |
| Additional paid-in capital | 142,274 | 151,614 |
| Accumulated other comprehensive loss | (6,603) | (6,659) |
| Accumulated deficit | (677,437) | (558,763) |
| Total stockholders’ equity | 464,806 | 492,956 |
| Total liabilities and stockholders’ equity | $580,880 | $648,725 |
| Research collaboration and licensing agreements (note 12) | ||
| Commitments and contingencies (note 16) | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.